Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.56 |
| ▸ | GAA | P10253 | 2/20 | 0.56 |
| ▸ | TP53 | P04637 | 1/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | SLC12A2 | P55011 | 1/20 | 0.52 |
| ▸ | SLC12A5 | Q9H2X9 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | GLA | P06280 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2875837 | 0.92 | LMNA (0.55) | ALDH1A1GAATDP1KDM4ECYP1A2 | |
| SCHEMBL4521279 | 0.82 | TDP1 (0.64) | ALDH1A1GAATP53TDP1LMNA | |
| SCHEMBL3913371 | 0.77 | ALDH1A1 (0.79) | ALDH1A1GAATP53KDM4ELMNA | |
| SCHEMBL2875881 | 0.77 | ALDH1A1 (0.58) | ALDH1A1GAATP53TDP1KDM4E | |
| SCHEMBL1287486 | 0.77 | CYP1A2 (0.68) | ALDH1A1GAATP53TDP1KDM4E | |
| SCHEMBL2881016 | 0.76 | ALDH1A1 (0.64) | ALDH1A1TP53POLB | |
| SCHEMBL2875009 | 0.76 | ACLY (0.65) | ALDH1A1LMNAPOLBGLA | |
| SCHEMBL2875369 | 0.75 | POLB (0.50) | ALDH1A1GAATP53TDP1KDM4E | |
| SCHEMBL2877986 | 0.74 | CA12 (0.54) | ALDH1A1POLBGLA | |
| SCHEMBL3409768 | 0.74 | GSTO1 (0.62) | ALDH1A1GAAKDM4ELMNAPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2066628-B1 | 2-PHENYL-INDOLES AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS | SANOFI AVENTIS (FR) | 2010-10-20 | — | — | EP | disclosed |
| US-20090176804-A1 | 2-PHENYL-INDOLES AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS | SANOFI-AVENTIS (FR) | 2009-07-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090176804-A1 | 2-PHENYL-INDOLES AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS | PTGER2, PTGDR2, CYSLTR2 | ALDH1A1 1757/4885GAA 3522/4885TP53 3735/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.